Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OTX-TIC · 1 trial · 2 indications
All adverse events will be captured throughout the study
IOP measurements at 8 am
| Arm | Type | Description |
|---|---|---|
| OTX-TIC-Cohort 1 | EXPERIMENTAL | 15 µg (formulation1) implant |
| OTX-TIC-Cohort 2 | EXPERIMENTAL | 26 µg (formulation1) implant |
| OTX-TIC-Cohort 3 | EXPERIMENTAL | 15 µg (formulation 2) implant |
| OTX-TIC-Cohort 4 | EXPERIMENTAL | 5 µg (formulation 3) implant |
| Name | Type | Description |
|---|---|---|
| OTX-TIC | DRUG | OTX-TIC implant is injection in the anterior chamber of the eye |
Inclusion Criteria: * Have a documented diagnosis of ocular hypertension or primary open-angle glaucoma * Have IOP that is currently controlled as assessed by the Investigator * Have open, normal appearing anterior chamber angles as determined by gonioscopy Exclusion Criteria: * Have closed angle...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
OTX-TIC is an investigational small molecule being developed for ocular hypertension. It is also being studied in open angle glaucoma, as the completed Phase 1 trial enrolled participants with either condition. The drug is administered in the eye and is intended to lower intraocular pressure.
OTX-TIC is being developed by Ocular Therapeutix, Inc., a biopharmaceutical company traded on NASDAQ under the ticker OCUL. The company is focused on ophthalmology and is evaluating this small molecule in a Phase 1 clinical trial for ocular hypertension.
OTX-TIC is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by the FDA, and its safety and efficacy are still being evaluated in clinical studies.
OTX-TIC has one completed clinical trial, NCT04360174, titled 'CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension.' This Phase 1 study enrolled 19 participants in the United States and was not randomized or double-blinded.
OTX-TIC is a small molecule designed to treat ocular hypertension. Its specific molecular target has not been disclosed, so the exact mechanism of action is not publicly detailed. The drug is being studied for its ability to lower intraocular pressure in patients with ocular hypertension or open angle glaucoma.